HK Stock Market Move | CHERVON (02285) rose by over 11% recently announced plans to repurchase up to 1.5 billion Hong Kong dollars worth of shares.
Spring Peak Holdings (02285) rose more than 11%, as of press time, up 11.28% to HK$16.67, with a turnover of HK$58.0535 million.
CHERVON (02285) rose by over 11%, with a increase of 11.28% at the time of publication, closing at HK$16.67 with a turnover of HK$58.05 million.
On the news front, CHERVON recently announced a share repurchase plan to be implemented from June 8, 2026 to December 31, 2026, during which the company can repurchase up to HK$150 million worth of common shares. The share repurchase plan will be implemented by exercising the power granted by the board of directors under the existing general authorization to repurchase shares given by the shareholders at the annual general meeting held on May 18, 2026.
Guotai Haitong previously pointed out that the company is a global leading gardening tool enterprise. Building around core technologies such as battery platform, battery management system, motor, and electronic control, it has established a matrix of five differentiated brands including EGO, SKIL, FLEX, DAYOU, and XIAOQIANG. Leveraging its long-term accumulation of R&D innovation capability, brand operation capability, and global channel system, the company has established a strong first-mover advantage and competitive barrier in the OPE track of lithium-ionization.
Related Articles

QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.
QYUNS-B (02509) spent HKD 159,600 to buy back 10,000 shares on June 12th.

RONGTA TECH (09881) suggests the removal of Luo Bingxian Yongdao from the position of company auditor.

SIMCERE PHARMA (02096): SIM0689 (PD-1/VEGF dual-specific antibody) has obtained the drug clinical trial approval notice issued by the National Medical Products Administration.

RECOMMEND





